CyFlow HLA-B7 Purified (RUO)
| 品番 | AF692459 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu HLA-B7 PURI,BB7.1 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 Purified (BJ561896) Mouse IgG1 Purified (AS224818) |
||
| 反応性|交差吸着 | Human | Non-Human Primates | レーザー | - |
| 抗原 | HLA-B7 | 最大蛍光波長 | - |
| クローン | BB7.1 | 最大励起波長 | - |
| ホスト | Mouse | 標識/Format | Purified |
| アイソタイプ | IgG1 | 研究分野 | MHC |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu HLA-B7 PURI,BB7.1
特異性
The mouse monoclonal antibody BB7.1 recognizes the HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
抗原情報
HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22% of healthy Caucasian individuals.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Bhattacharya P, Sengupta S: Predisposition to HPV16/18‑related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA‑B*07 and homozygosity of HLA‑DQB1*03. Tissue·Antigens. 2007·Oct; 70(4):283‑93. <·PMID:·17767549·>
• Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA‑B7‑restricted peptides of hTRT. Int·Immunol. 2006·Dec; 18(12):1707‑18. <·PMID:·17077179·>
• de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin·Exp·Immunol. 2002·Jun; 128(3):525‑31. <·PMID:·12067308·>
• Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am·J·Respir·Crit·Care·Med. 2004·Mar·15; 169(6):696‑702. <·PMID:·14656748·>
• Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA‑B*27/HLA‑B*07 in combination with D6S273‑134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. Clin·Exp·Rheumatol. 2008·May-Jun; 26(3):498‑504. <·PMID:·18578977·>
• Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I‑associated tumor peptides by Nano‑LC MALDI MS/MS. Mol·Cell·Proteomics. 2005·Dec; 4(12):1888‑97. <·PMID:·16112985·>
• Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA‑E: strong association with beta2‑microglobulin and surface expression in the absence of HLA class I signal sequence‑derived peptides. Immunol. 2008·Oct·15; 181(8):5442‑50. <·PMID:·18832701·>
• Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA‑liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc·Natl·Acad·Sci·USA. 1993·Dec·1; 90(23):11307‑11. <·PMID:·8248244·>
• Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA‑B7 into metastatic renal carcinoma lesions. Clin·Cancer·Res. 1999·Oct; 5(10):2766‑72. <·PMID:·10537340·>
• Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc·Natl·Acad·Sci·USA. 1989·Apr; 86(7):2361‑4. <·PMID:·2784569·>
• Trapani JA, Vaughan HA, Tait BD, McKenzie IF: Immunoradiometric assay for the rapid detection of HLA‑B27. Immunol·Cell·Biol. 1988·Jan; 66 ( 3):215‑9. <·PMID:·3155158·>
• Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population‑based study in Costa Rica. J·Infect·Dis. 2001·Nov·15; 184(10):1310‑4. <·PMID:·11679920·>
• Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma‑associated chromosomal translocations. Cancer·Res. 2001·Sep·15; 61(18):6868‑75. <·PMID:·11559563·>